Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn’s disease: results from the multicentre retrospective real-life study MUST
This study found that immediate escalation of ustekinumab therapy to 4-weekly dosing could achieve higher remission rates at one year than 8-weekly dosing in refractory CD.
Authors
- Mathieu Niquille (ORCID: https://orcid.org/0000-0002-2860-3861)
- A Abdelmoula
- Sandie Pestour (ORCID: https://orcid.org/0000-0003-4723-9222)
- Xavier Roblin (ORCID: https://orcid.org/0000-0002-7929-4878)
- Stéphane Nancey (ORCID: https://orcid.org/0000-0003-2088-1442)
- M Hupé
- T Chateau
- Claire Gay (ORCID: https://orcid.org/0000-0002-0152-8136)
- Gilles Boschetti (ORCID: https://orcid.org/0000-0003-4039-7607)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Hospices Civils de Lyon (FR)
- Grenoble Institute of Neurosciences (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Digestive and Liver Disease
- Published
- 2025-06-07
- DOI
- https://doi.org/10.1016/j.dld.2025.05.024
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82